ORG – Page 3 – Talk Bio

Stealth biotech bags rights to VelaVigo bispecific in $440M deal

6 days ago talkbio0Tagged Antibodies, Bispecific, China, stealth, VelaVigo

VelaVigo, Antibodies, Bispecific, stealth, China

UK approval brings GSK’s Blenrep back from the brink

6 days ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Blenrep, Cessation of life, dexamethasone, DREAMM-8, Multiple Myeloma, Risk, UK

UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

6 days ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

1 week ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format

FDA clears its first prescription migraine app, from Click Therapeutics

1 week ago talkbio0Tagged click, Click Therapeutics, CT-132, first, Migraine Disorders, United States Food and Drug Administration

United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

1 week ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines

1 week ago talkbio0Tagged Autistic Disorder, Environment, HHS, Kennedy, RFK gene, Vaccines

Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

1 week ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

1 week ago talkbio0Tagged Alarm device, Changing, Disease Outbreaks, drug safety, Icebergs, KAT5 wt Allele, Leadership, Policy, Previous, public health medicine (field), United States Food and Drug Administration, Vaccines, Visible

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible

UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU

1 week ago talkbio0Tagged drug price, EU, Industry, Investments, Pharma, Policy, Transplant Registry Unified Management Program, United States

EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price